Quetiapine in the Treatment of Postpartum Depression (PPD) in Bipolar Disorder (BD), Type II
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This is a 9-week single-centre, open-label, dose-escalating study evaluating the efficacy and
safety of Quetiapine XR given as monotherapy in the treatment of non-lactating, post-partum
women diagnosed with Bipolar II Disorder. Subjects will need to visit the study doctor up to
8 times over a period of 9 weeks.
During the study period, subjects will be receiving a treatment with Quetiapine XR. The
starting dose of quetiapine that subjects will receive is 50mg. The response to the treatment
of quetiapine will determine whether the study doctor will increase the dosage of the
subject's quetiapine. If the study doctor increases the quetiapine during the study, the
maximum dosage allowable during the study is 300mg.